<DOC>
	<DOC>NCT00958334</DOC>
	<brief_summary>ZPU-003 EXT is a 2-year extension study of ZPU-003 to determine the continued safety and efficacy of Proellex in women who have previously completed the double-blind portion of the study.</brief_summary>
	<brief_title>Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003</brief_title>
	<detailed_description>ZPU-003 EXT is a 2-year extension study of ZPU-003. The purpose of the study is to determine the continued safety and efficacy of Proellex in women who have previously completed the double-blind portion of the study. The desired primary efficacy outcome will be a changes in vaginal bleeding from baseline to 14 months and 17 months on study drug. The total duration of the study is up to 24 months including transition times, off drug intervals, and follow-up visits). It is expected that over a 16 week on drug interval menses will subside and return after a 4-8 week off drug interval (ODI).</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<criteria>Completed the ZPU 003 study and met the inclusion/exclusion criteria of that study. Low or high grade cervical dysplasia, as determined by Papanicolaou (PAP) smear. Pregnant or breastfeeding.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Uterine fibroids</keyword>
</DOC>